Back to GetFilings.com

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2003

OR

FOR THE TRANSITION PERIOD FROM                      TO                     

Commission file number 0-26816

IDX SYSTEMS CORPORATION

(Exact Name of Registrant as Specified in Its Charter)

40 IDX Drive

South Burlington, VT 05403

(Address of Principal Executive Offices)

Registrant’s Telephone Number, Including Area Code: (802-862-1022)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.

Yes x             No ¨

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 126-2 of the Exchange Act).

Yes x             No ¨

The number of shares outstanding of the registrant’s common stock as of May 5, 2003 was 29,235,177.

Page 1 of 38

Table of Contents

IDX SYSTEMS CORPORATION

FORM 10-Q

For the Period Ended March 31, 2003

TABLE OF CONTENTS

Page 2 of 38

Table of Contents

PART I.    FINANCIAL INFORMATION

Item 1.    Interim Financial Statements

IDX Systems Corporation

Condensed Consolidated Balance Sheets

(in thousands)

(unaudited)

See Notes to Condensed Consolidated Financial Statements.

Page 3 of 38

Table of Contents

PART I.    FINANCIAL INFORMATION

Item 1.    Interim Financial Statements

IDX Systems Corporation

Condensed Consolidated Statements of Income

(in thousands, except for per share data)

(unaudited)

See Notes to Condensed Consolidated Financial Statements.

Page 4 of 38

Table of Contents

PART I.    FINANCIAL INFORMATION

Item 1.    Interim Financial Statements

IDX Systems Corporation

Condensed Consolidated Statements of Cash Flows

(in thousands)

(unaudited)

See Notes to Condensed Consolidated Financial Statements.

Page 5 of 38

Table of Contents

Notes to Condensed Consolidated Financial Statements

Note 1 – Nature of Business and Basis of Presentation

IDX Systems Corporation (“IDX” or the “Company”) provides healthcare information systems and services to large integrated healthcare delivery enterprises principally located in the United States and Canada. Revenues are derived from the licensing of software, hardware sales, provision of maintenance and services related to systems sales and provision of medical transcription services.

On April 10, 2003, IDX and Total eMed, Inc. (“Total eMed”), a medical transcription company based in Franklin, Tennessee, entered into a definitive agreement whereby Total eMed will acquire EDiX Corporation (“EDiX”), a wholly owned subsidiary of IDX. In exchange for all the outstanding shares of capital stock of EDiX, IDX will receive approximately $64.0 million in cash. The purchase price will be adjusted on a dollar for dollar basis to reflect the difference, if any, between $18.1 million and the working capital of EDiX as of the transaction closing date. EDiX will be accounted for as a discontinued operation beginning with the reporting of the Company’s second quarter 2003 results. EDiX did not qualify for treatment as a discontinued operation as of March 31, 2003. The sale transaction is scheduled to close subject to customary closing conditions, including the expiration of the waiting period under the Hart-Scott-Rodino Act, on May 31, 2003.

The interim unaudited condensed consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission and in accordance with accounting principles generally accepted in the United States. Accordingly, certain information and footnote disclosures normally included in annual financial statements have been omitted or condensed. In the opinion of management, all necessary adjustments (consisting of normal recurring accruals and adjustments) have been made to provide a fair presentation. The operating results for the three months ended March 31, 2003 are not necessarily indicative of the results that may be expected for the year ending December 31, 2003. For further information, refer to the consolidated financial statements and accompanying notes included in the Company’s Annual Report on Form 10-K filed for the year ended December 31, 2002, with the Securities and Exchange Commission on March 31, 2003.

Note 2 – Accounting for Stock Based Compensation.

The Company accounts for its stock-based compensation plan under Accounting Principal Bulletin Opinion (“APB”) No. 25, Accounting for Stock Issued to Employees. Statement of Financial Accounting Standard (SFAS) No. 123, Accounting for Stock-Based Compensation, establishes the fair-value-based method of accounting for stock-based compensation plans. The Company has adopted the disclosure-only alternative for options granted to employees and directors under SFAS No. 123, which requires disclosure of the pro forma effects on earnings as if SFAS No. 123 had been adopted, as well as certain other information. Options granted to scientific advisory board members and other non-employees are recorded at fair value based on the fair value measurement criteria of SFAS No. 123.

The Company has computed the pro forma disclosures required under SFAS No. 123 for all stock options granted to employees and directors of the Company as of March 31, 2003 and 2002, using the Black-Scholes option pricing model prescribed by SFAS No. 123.

Page 6 of 38

Table of Contents

The assumptions used for the periods ended March 31, 2003 and 2002 are as follows:

The effect of applying SFAS No. 123 would be as follows:

Note 3 – New Accounting Standards

In November 2002, the Financial Accounting Standards Board (“FASB”) issued FASB Interpretation No. (“FIN”) 45, “Guarantor’s Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others.” FIN 45 requires that upon issuance of a guarantee, the guarantor must recognize a liability for the fair value of the obligation it assumes under the guarantee. The disclosure provisions of FIN 45 are effective for financial statements of interim or annual periods ending after December 15, 2002. The provisions for initial recognition and measurement are effective on a prospective basis for guarantees that are issued or modified after December 31, 2002, irrespective of a guarantor’s fiscal year-end. The adoption of FIN 45 has not had a material impact on the Company’s consolidated results of operations or financial position.

In January 2003, the FASB issued FIN 46, “Consolidation of Variable Interest Entities,” to expand upon and strengthen existing accounting guidance that addresses when a company should include in its financial statements the assets, liabilities and activities of another entity. Until now, a company generally has included another entity in its consolidated financial statements only if it controlled the entity through voting interests. FIN 46 changes that guidance by requiring a variable interest entity, as defined, to be consolidated by a company if that company is subject to a majority of the risk of loss from the variable interest entity’s activities or is entitled to receive a majority of the entity’s residual returns or both. FIN 46 also requires disclosure about variable interest entities that the company is not required to consolidate but in which it has a significant variable interest. The consolidation requirements of FIN 46 apply immediately to variable interest entities created after January 31, 2003 and to older entities in the first fiscal year or interim period beginning after June 15, 2003. Certain of the disclosure requirements apply in all financial statements issued after January 31, 2003, regardless of when

Page 7 of 38

Table of Contents

the variable interest entity was established. The Company is currently evaluating the requirements and impact, if any, of FIN 46 on its consolidated results of operations and financial position.

In June 2002, the FASB issued Statement of Financial Accounting Standard (“SFAS”) No. 146, “Costs Associated with Exit or Disposal Activities.” SFAS 146 supercedes Emerging Issues Task Force (“EITF”) Issue No. 94-3, “Liability Recognition for Certain Employee Termination Benefits and Other Costs to Exit an Activity”. SFAS No. 146 requires that a liability for a cost associated with an exit or disposal activity be recognized and measured initially at fair value only when the liability is incurred. SFAS No. 146 is effective for exit or disposal activities that are initiated after December 31, 2002. The adoption of SFAS No. 146 did not have a material impact on the Company’s financial position or results of its operations.

In December 2002, the FASB issued SFAS No. 148, “Accounting for Stock-Based Compensation—Transition Disclosure, An Amendment of FASB Statement No. 123”. SFAS No. 148 provides alternative methods of transition for a voluntary change to the fair value based method of accounting for stock-based employee compensation. In addition, SFAS No. 148 amends the disclosure requirements of SFAS No. 123 to require more prominent and more frequent disclosure in financial statements regarding the effects of stock-based compensation. The provisions of SFAS No. 148 are effective for fiscal and interim periods ending after December 15, 2002. The Company will continue to apply Accounting Principles Board (“APB”) No. 25 as the method used to account for stock-based employee compensation arrangements, where applicable, but has adopted the disclosure requirements of SFAS No. 148.

Note 4 – Business Combinations and Divestitures

In April 2002, the Company acquired a minority interest in Stentor, Inc. (“Stentor”), one of the Company’s strategic partners, by exercising a warrant to purchase 562,069 shares of preferred stock of Stentor. The Company paid approximately $7.5 million to purchase the preferred shares. Stentor is a California based medical informatics company with products for medical image and information management. The warrant was issued to the Company in November 2000 in connection with an alliance agreement that was entered into by the parties to jointly develop a medical image and information management system (“MIMS”) combining the Company’s Imaging Suite^™ product with the image distribution technology from Stentor. This investment will be carried at cost. There is currently no public market for the preferred shares of Stentor.

On January 8, 2001, the Company sold certain operations of its majority owned subsidiary, ChannelHealth Incorporated (“ChannelHealth”) to Allscripts Healthcare Solutions, Inc. (“Allscripts”), a leading provider of point-of-care e-prescribing and productivity solutions for physicians. In addition to the sale, the Company entered into a ten-year strategic alliance whereby Allscripts is the exclusive provider of point-of-care clinical applications sold by IDX to physician practices.

In exchange for its 87% ownership of ChannelHealth, IDX received approximately 7.5 million shares (subject to certain resale restrictions as discussed below) of Allscripts common stock, which represented approximately a 20% ownership interest in Allscripts. IDX recorded these shares of Allscripts common stock at an estimated fair value of $29.5 million, which included a discount from market value due to restrictions on transfer. At the time of the transaction, ChannelHealth’s liabilities exceeded its assets by $10.5 million, resulting in a gain of approximately $40 million. Pursuant to the Alliance Agreement, IDX guaranteed that Allscript’s gross revenues resulting from the alliance (less any commissions paid to IDX) would amount to at least $4.5 million for fiscal year 2001. Due to this contingency, IDX deferred $4.5 million of the gain as of the date of the transaction and recognized a gain of $35.5 million in 2001. An additional gain of $4.3 million was recognized in the first quarter of 2002 when the contingency was resolved.

IDX accounts for its investment in Allscripts under the equity method of accounting. Under the equity method of accounting, IDX recognized its pro-rata share of Allscripts 2001 losses resulting in the elimination of the carrying value of this investment during the third quarter of 2001. IDX has not recorded its share of Allscripts losses since then. As of March 31,2003, the Company’s share of Allscripts losses amounts to $68.1 million. At March 31, 2003, the estimated market value of the Company’s investment in Allscripts is approximately $20.6 million based on the closing price per share of Allscripts common stock on the NASDAQ National Market. The fair market value would be discounted to reflect the Company’s restricted ability to sell only 25% of its initial shares of Allscripts common stock in any one year.

Page 8 of 38

Table of Contents

Through March 31, 2003, the Company has sold approximately 14,000 shares of Allscripts common stock, which has not materially changed its ownership interest in Allscripts.

Summary audited financial information for Allscripts for 2002 is as follows (in thousands):

Summary unaudited financial information for Allscripts for the first quarter of 2003 and 2002 is as follows (in thousands):

Note 5 – Lease Abandonment Charge

In 1999, the Company entered into a lease for new office space in Seattle. Although the Company continued to utilize the existing space, an active search for a sublessor was initiated and has been ongoing. In 2002, the Company determined it would consolidate its Seattle operations into the new office space and abandoned the space subject to the former lease. Due to the depressed Seattle real estate market and the inability to obtain a sublessor, the Company recorded a lease abandonment charge of $9.2 million in its core information systems and services business segment in the fourth quarter of 2002. The lease abandonment charge is related to lease payments of approximately $7.9 million through the end of the lease term in 2005 and non-cash write-offs of certain leasehold improvements of approximately $1.3 million. As of December 31, 2002, the Company had an accrual balance of $9.2 million. During the first quarter of 2003, leasehold improvements of $1.3 million were written off and lease payments of approximately $800,000 were made. Of the $7.1 million accrual remaining at March 31, 2003, approximately $2.2 million will be paid during the remainder of 2003 and approximately $4.9 million thereafter. In the event that the Company is able to secure a sub-tenant to assume its prior lease in a future reporting period, the present value of the future sub-lease income would be recorded as a reduction in expenses under the lease abandonment caption in the financial statements in the period in which the sub-lease agreement is signed.

Note 6 – Restructuring Charges

On September 28, 2001, the Company announced its plan to restructure and realign its large physician group practice business. The Company implemented a workforce reduction and restructuring program affecting approximately four percent of the Company’s employees. The restructuring program resulted in a charge to earnings of approximately $19.5 million during the fourth quarter of 2001, comprised of costs associated with employee severance arrangements of approximately $5.5 million, lease payment costs of approximately $5.2 million and equipment and leasehold improvement write-offs related to the leased facilities and workforce reduction of $8.8 million. Substantially all workforce reduction related actions were completed during the fourth quarter of 2001. As of December 31, 2002, the Company had an accrual balance of $2.9 million, primarily

Page 9 of 38

Table of Contents

related to leased facilities, of which approximately $600,000 was paid during the first quarter of 2003. Of the $2.3 million accrual balance at March 31, 2003, approximately $1.2 million will be paid during the remainder of 2003 and approximately $1.1 million thereafter.

Note 7 – Segment Information

The Company views its operations and manages its business as principally two segments; information systems and services that include software, hardware and related services, and medical transcription services. The Company’s business units have separate management teams and infrastructures that offer different products and services. Accordingly, these business units have been classified as reportable segments.

Information Systems and Services: This reportable segment consists of IDX’s healthcare information solutions that include software, hardware and related services. IDX solutions enable healthcare organizations to redesign patient care and other workflow processes in order to improve efficiency and quality. The principal markets for this segment include physician groups, management service organizations, hospitals and integrated delivery networks primarily located in the United States and Canada.

Medical Transcription Services: This reportable segment consists of EDiX, a provider of medical transcription outsourcing services. The principal markets for this segment include hospitals and large physician group practices primarily located in the United States. Upon successful completion of the sale of EDiX to Total eMed, Inc. (see Note 11), the Company’s operations will be represented by one operating segment.

The accounting policies of the reportable segments are the same as those described in Note 1 of the Notes to the Consolidated Financial Statements included in Company’s Annual Report on Form 10-K for the year ended December 31, 2002.

The Company evaluates the performance of its operating segments based on revenue and operating income. Intersegment revenues are immaterial. No one customer accounts for greater than 10% of revenue for either reportable segment.

Page 10 of 38

Table of Contents

Summarized financial information concerning the Company’s reportable segments is shown (in thousands) in the following table:

Corporate headquarters assets and related operating costs are included in the Information Systems and Services segment information. Substantially all of the Company’s operations are in the United States.

Note 8 – Accrued Expenses

Accrued expenses consist of the following:

Note 9 – Income Taxes

The Company’s 2003 and 2002 effective tax rate is lower than the statutory rate, primarily due to research credits. The net deferred tax assets as of March 31, 2003 of approximately $3.6 million are expected to be realized by generating future taxable income and are otherwise recoverable through available tax planning strategies.

Note 10 – Comprehensive Income

Total comprehensive income for the quarter ended March 31, 2003 amounted to $3.8 million compared to $4.1 million for the same period in 2002. Comprehensive income (loss) includes unrealized gains or (losses) on the Company’s marketable securities that are included as a component of stockholders’ equity.

Page 11 of 38

Table of Contents

Note 11 – Earnings Per Share Information

The following sets forth the computation of basic and diluted earnings per share:

(in thousands, except for per share data)

Options to acquire 2,832,783 and 3,170,782 shares of the Company’s common stock for the three months ended March 31, 2003 and 2002, respectively, were excluded from the calculation of diluted earnings per share, as the effect would not have been dilutive.

Note 12 – Financing Arrangements

The Company has a revolving line of credit agreement (the “Line”) allowing the Company to borrow up to $40.0 million subject to certain restrictions. The New Line is secured by deposit accounts, accounts receivable and other assets and bears interest at the bank’s base rate plus .25%. The Line will expire on June 27, 2005. At March 31, 2003, the Company had $23.7 million outstanding under this arrangement. As of the quarter ended March 30, 2003, the Company was in violation of minimum cash flow requirements giving the creditor the right to require us to repay the entire value of the Line at any time. Amounts due under the Line were paid in full on April 1, 2003. The Company has received a waiver from the creditor for the quarter ended March 30, 2003.

The Company has a $2.8 million stand-by letter of credit arrangement with a bank in compliance with a provision of an office space lease related to tenant improvements. The Company has no plans to default on the underlying payment obligation, and therefore has determined that the fair value of this contingent liability is zero. This stand-by letter of credit expires in June 2003.

Note 13 – Subsequent Event

On April 10, 2003, IDX and Total eMed, Inc. Total eMed, a medical transcription company based in Franklin, Tennessee, entered into a definitive agreement whereby Total eMed will acquire EDiX Corporation, a wholly owned subsidiary of IDX. In exchange for all the outstanding shares of capital stock of EDiX, IDX will receive approximately $64.0 million in cash. The purchase price will be adjusted on a dollar for dollar basis to reflect the difference, if any, between $18.1 million and the working capital of EDiX as of the transaction closing date. EDiX will be accounted for as a discontinued operation beginning with the reporting of the Company’s second quarter 2003 results. EDiX did not qualify for treatment as a discontinued operation as of March 31, 2003. The sale transaction is scheduled to close subject to customary closing conditions, including the expiration of the waiting period under the Hart-Scott-Rodino Act, on May 31, 2003.

Page 12 of 38

Table of Contents

Presented below (in thousands) are the carrying amounts of the major assets and liabilities of EDiX as of March 31, 2003 and December 31, 2002.

Note 14 – Legal Proceedings

In late 2001, IDX finalized a “Cooperative Agreement” with a non-regulatory federal agency within the U.S. Commerce Department's Technology Administration, NIST, whereby the Company agreed to lead a $9.2 million, multi-year project awarded by NIST. The project entails research and development to be conducted by IDX and its partners in the grant. Subsequently, an employee of the Company made allegations that the Company had illegally submitted claims for labor expenses and license fees to NIST. The Company informed NIST of the employee’s allegations. The Company has conducted an investigation, and based on this investigation, the Company believes the employee’s allegations are without merit.

The Company believes the employee has likely filed an action under the Federal False Claims Act under seal in the Federal District Court for the Western District of Washington with respect to the alleged improper claims, sometimes referred to as a “Qui Tam” complaint. The Company has no information regarding the specific allegations in the Qui Tam complaint. Further, the Company has no information concerning the amount of money at issue in the Qui Tam complaint or in any action the employee may bring claiming damages for alleged retaliatory actions by the Company. The Company has not been informed if the U.S. Attorney’s office will pursue the claims. The Company has not yet been served with legal process detailing the allegations and no discovery has taken place. The Company believes that any allegations in the Qui Tam complaint are without merit, and the Company intends to vigorously defend against them.

Page 13 of 38

Table of Contents

In April 2003, the Company filed a complaint against the employee with the United States District Court for the Western District of Washington. The Company’s lawsuit asks the Court to grant a declaratory judgment stating that, should the Company terminate the employee’s employment, such action would not constitute retaliation for alleged whistle-blowing activities in violation of the Federal False Claims Act or the Sarbanes-Oxley Act and would not constitute a violation of the employee’s rights under other laws. The Company believes its lawsuit is meritorious and intends to vigorously pursue relief through prosecution of the lawsuit.

In May 2003, the employee filed a complaint against the Company with the U.S. Department of Labor, pursuant to Section 1514A of the Sarbanes-Oxley Act of 2002. The employee’s complaint asserts that, notwithstanding the employee’s allegations, Company management conspired to continue to defraud the government by allowing fraudulent activities to continue uncorrected and by concealing and avoiding its obligations to report any and all fraudulent activities to the proper authorities. In addition, the employee’s complaint alleges that the Company acted to retaliate, harass and intimidate the employee in contravention of the Sarbanes-Oxley Act’s whistleblower provisions. The employee’s complaint requests relief including, but not limited to, reinstatement, back-pay, with interest, and compensation for any damages sustained by the employee as a result of the alleged discrimination. The Company believes that all claims by the employee are without merit and will vigorously defend against them.

In April 2000, the Company commenced a lawsuit for damages caused by wrongful cancellation and material breach of contract by St. John Health System (SJHS), in the United States District Court for Eastern District of Michigan, entitled IDX Systems Corporation v. St. John Health System. Subsequently, SJHS commenced a lawsuit against the Company in the Circuit Court of Wayne County, Michigan, claiming unspecified damages against the Company for anticipatory repudiation, breach of contract, tort and fraud. On motion of the Company, SJHS’s lawsuit was removed to and consolidated in the federal court. In its answer to the Company’s lawsuit, SJHS asserted the same claims previously asserted in its state court action. In September 2001, SJHS specified damage claims of approximately $77.0 million in allegedly lost savings, and in January 2002 raised another theory of alleged unspecified damages for “cover.” On September 30, 2002, the United States District Court for the Eastern District of Michigan dismissed all of SJHS claims of fraud, tort and breach of contract, and alleged lost savings and consequential damages, leaving only its claim for anticipatory repudiation. On October 15, 2002, SJHS requested reconsideration of these rulings. On March 28, 2003, the Court denied SJHS’s request for reconsideration of its September ruling and also barred SJHS from introducing any evidence concerning, or making any arguments concerning, its claims for “cover” damages. The Company believes the claims of SJHS are without merit and continues to vigorously defend itself and prosecute its own claims for damages. The lawsuit is in the trial preparation stage and the parties are awaiting scheduling of the trial by the court.

From time to time, the Company is a party to or may be threatened with litigation in the ordinary course of its business. The Company regularly analyzes current information including, as applicable, the Company’s defenses and insurance coverage and, as necessary, provides accruals for probable and estimable liabilities for the eventual disposition of these matters.

Page 14 of 38

Table of Contents

Item 2.    Management’s Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion together with the consolidated condensed financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q. This Item contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934 that involve risks and uncertainties. Actual results may differ materially from those included in such forward-looking statements. Factors which could cause actual results to differ materially include those set forth under “Forward-Looking Information and Factors Affecting Future Performance”, as well as those otherwise discussed in this section and elsewhere in this Quarterly Report on Form 10-Q. Unless otherwise specified or the context requires otherwise, the terms “we”, “us”, “our” and the “Company” refer to IDX Systems Corporation and its subsidiaries.

GENERAL

Founded in 1969, IDX Systems Corporation provides information technology (software and service) solutions to maximize value in the delivery of healthcare by improving the quality of patient service, enhancing medical outcomes and reducing the costs of care. Healthcare providers purchase IDX systems, which are designed to be complementary and functionally rich; to improve their patients’ experience through simpler access, safer care delivery and more streamlined accounting.

Revenue growth is driven by demand for new healthcare information technology systems and services as well as installation, maintenance and service to our existing customers, which total more than 3,600 installation sites and include more than 138,000 physicians. Earnings growth is driven primarily by software sales, which yield significantly higher gross profit margins than our other revenue components – hardware and services.

We believe our biggest opportunity for both revenue and earnings growth will be driven by the increasing demand for safer care delivery and improved business performance – both of which we believe can be significantly improved through automation.

We measure financial performance by monitoring revenue and backlog from systems and services, days sales outstanding, recurring revenue, gross profit margin, operating profit margin and bookings.

Revenues increased to $121.1 million for the first quarter of 2003 from $107.8 million for the same period in 2002. Systems sales, which include software and hardware sales, increased 19.6% in the first quarter of 2003, while maintenance and service fees grew 9.8% as compared to the same period in the prior year. The increase in 2003 revenues reflect increased demand for software, hardware and services.

We reported operating income of $5.3 million for the first quarter of 2003 as compared to operating income of $1.6 million for the same period in 2002, an increase of $3.7 million. In the first quarter of 2003, we reported net income of $3.8 million, or $0.13 per share, as compared to net income of $4.1 million, or $0.14 per share, for the same period in 2002, a decrease of approximately $300,000. First quarter 2002 net income includes a pre-tax one-time gain of $4.3 million associated with the sale of ChannelHealth, a subsidiary. Excluding the $4.3 million gain and the related tax expense of approximately $1.4 million, 2002 first quarter net income was $1.3 million or $0.04 per fully diluted share.

We consider operating results excluding special items to be the most relevant benchmark of our core operating performance. Our management believes this pro forma measure helps indicate underlying trends in our business performance and uses this measure to manage the business and evaluate our performance. A reconciliation of pro forma to GAAP is included below:

Page 15 of 38

Table of Contents

On April 10, 2003, we entered into a definitive Stock Purchase and Sale Agreement with Total eMed, Inc., a medical transcription company based in Franklin, Tennessee, whereby Total eMed will acquire our wholly owned subsidiary, EDiX Corporation. In exchange for all the outstanding shares of capital stock of EDiX, IDX will receive approximately $64.0 million in cash. The purchase price will be adjusted on a dollar for dollar basis to reflect the difference, if any, between $18.1 million and the working capital of EDiX as of the transaction closing date. EDiX will be accounted for as a discontinued operation beginning with the reporting of the Company’s second quarter 2003 results. EDiX did not qualify for treatment as a discontinued operation as of March 31, 2003. The sale transaction is scheduled to close subject to customary closing conditions, including the expiration of the waiting period under the Hart-Scott-Rodino Act, on May 31, 2003.

Effective with the close of the sale of EDiX, we will no longer provide medical transcription outsourcing services. The principal markets for this reportable segment include hospitals and large physician group practices located throughout the United States and Canada. IDX will continue to focus on its flagship offerings, Flowcast, Groupcast, Carecast and Imagecast, which management believes present significant potential for both revenue and earnings growth.

We expect the sale of EDiX to result in a gain that will be recorded in the second quarter of 2003. Any severance, asset impairment or occupancy costs related to this transaction will be accounted for in accordance with SFAS No. 146 “Accounting for Costs Associated with Exit or Disposal Activities”. The sale is expected to have a positive effect on our liquidity due to the sales proceeds, net of any income taxes, and any future investments of such cash proceeds.

In our earnings announcement, dated April 30, 2003, we indicated that we remained comfortable with our 2003 revenue guidance of $400.0-$406.0 million from continuing operations and earnings guidance of $0.73 per share from continuing operations. This guidance assumes a 30% tax rate and no special items in 2003.

CRITICAL ACCOUNTING POLICIES

The discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amount of assets and liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities at the date of our financial statements. Those estimates are based on our experience; terms of existing contracts, our observance of trends in the industry, information provided by our customers and information available from other outside sources, which are believed to be reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions.

The following critical accounting policies affect the more significant judgments and estimates used in the preparation of our consolidated financial statements, and may potentially result in materially different results under different assumptions and conditions. We have identified the following as critical accounting policies to our Company:

Page 16 of 38

Table of Contents

This listing is not a comprehensive list of all of IDX’s’ accounting policies. For a detailed discussion on the application of these and other accounting policies, see Note 1 of Notes to Consolidated Financial Statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2002.

Revenue Recognition – We license software and sell hardware, related ancillary products and transcription services to customers through our direct sales force. We generally recognize revenue from software license, hardware, and related ancillary product revenues using the residual method when:

Under the residual method, we defer revenue recognition of the fair value of the undelivered elements and we allocate the remaining portion of the arrangement fee to the delivered elements and recognize it as revenue, assuming all other conditions for revenue recognition have been satisfied. We recognize substantially all of our product revenue in this manner. If we cannot determine the fair value of any undelivered element included in an arrangement, we will defer revenue recognition until all elements are delivered, services are performed or until fair value can be objectively determined.

As part of an arrangement, we typically sell maintenance contracts as well as professional services to customers. Maintenance services include telephone and Web-based support as well as rights to unspecified upgrades and enhancements, when and if we make them generally available. Professional services are deemed to be non-essential and typically are for implementation planning, loading of software, installation of hardware, training, building simple interfaces, running test data, and assisting in the development and documentation of process rules, and best practices consulting.

We recognize revenues from maintenance services ratably over the term of the maintenance contract period based on vendor specific objective evidence of fair value. Vendor specific objective evidence of fair value is based upon the amount charged for maintenance when purchased separately, which is typically the contract’s renewal rate. Maintenance services are typically stated separately in an arrangement.

We generally recognize revenues from professional services based on vendor specific objective evidence of fair value when: (1) a non-cancelable agreement for the services has been signed or a customer’s purchase order has been received; and (2) the professional services have been delivered. Vendor specific objective evidence of fair value is based upon the price charged when professional services are sold separately and is typically based on an hourly rate for professional services.

We generally recognize revenue from transcription services based on a reliable, verifiable and objectively determinable measure of fair value when: (1) a non-cancelable agreement for the services has been signed or a customer’s purchase order has been received; and (2) the transcription services have been delivered. We base the fair value of transcription services upon the price charged when these services are sold separately. Transcription services are typically charged at a per line rate.

Page 17 of 38

Table of Contents

Our arrangements with customers generally include acceptance provisions. However, these acceptance provisions are typically based on our standard acceptance provision, which provides the customer with a right to a refund if the arrangement is terminated because the product did not meet our published specifications. This right generally expires 30 days after installation. The product is deemed accepted unless the customer notifies us otherwise. Generally, we determine that these acceptance provisions are not substantive and historically have not been exercised, and therefore should be accounted for as a warranty in accordance with Statement of Financial Accounting Standards No. 5.

At the time we enter into an arrangement, we assess the probability of collection of the fee and the terms granted to the customer. Our typical payment terms include a deposit and subsequent payments based on specific milestone events and dates. Our payment terms are less than 90 days and typically amounts are due within 30 days of invoice date. If we consider the payment terms for the arrangement to be extended or if the arrangement includes a substantive acceptance provision, we defer revenue not meeting the criterion for recognition under SOP 97-2 and classify this revenue as deferred revenue, including deferred product revenue. We recognize deferred revenue, assuming all other conditions for revenue recognition have been satisfied, when the payment of the arrangement fee becomes due and/or when the uncertainty regarding acceptance is resolved as generally evidenced by written acceptance or payment of the arrangement fee.

Additionally, we periodically enter into certain long-term contracts where we generally recognize revenue on a percentage of completion basis using labor-input measures. We recognize losses, if any, on fixed price contracts when the loss is determined. We record revenue in excess of billings on long-term service contracts as unbilled receivables and include in trade accounts receivable. We record billings in excess of revenue recognized on service contracts as deferred revenue until revenue recognition criteria are met.

Allowance for Doubtful Accounts – IDX maintains an allowance for doubtful accounts to reflect estimated losses resulting from the inability of customers to make required payments. We base this allowance on estimates after consideration of factors such as the composition of the accounts receivable aging and bad debt history and our evaluation of the financial condition of the customers. If the financial condition of customers were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances and bad debt expense may be required. We typically do not require collateral. Historically, our estimates have been adequate to cover accounts receivable exposures.

Capitalization of Software Development Costs – We expense all costs incurred in the research, design and development of software for sale to others until technological feasibility is established. Technological feasibility is established when planning, designing, coding and testing activities have been completed so that the working model is consistent with the product design as confirmed by testing. Thereafter, we capitalize and amortize software development costs to software development expense on a straight-line basis over the lesser of 18 months or the estimated lives of the respective products, beginning when the products are offered for sale. We expense costs incurred in the development of software for internal use until it becomes probable that these developments will provide additional functionality that will benefit future periods. Thereafter, we capitalize and amortize certain costs to operating expense on a straight-line basis over the lesser of five years or the estimated economic life of the software. While we believe that our current estimates and the underlying assumptions regarding capitalized software development costs are appropriate, future events could necessitate adjustments to these estimates resulting in additional software development expense in the period of adjustment.

Income Taxes – Our valuation allowance relating to the net deferred tax assets is based on our assessment of historical pre-tax income as well as tax planning strategies designed to generate future taxable income. These strategies include estimates and involve judgment relating to certain unrealized gains in our investment in common stock of an equity investee. To the extent that facts and circumstances change, these tax-planning strategies may no longer be sufficient to support the deferred tax assets and we may be required to increase the valuation allowance. To the extent that we generate future taxable income against which these tax assets may be applied, some portion or all of the valuation allowance would be reversed and an increase in net income would consequently be reported in future years.

Page 18 of 38

Table of Contents

Restructuring and Lease Abandonment Charges – We have recorded restructuring and lease abandonment charges associated with restructuring plans approved by management over the last three years. These reserves include estimates pertaining to employee separation costs and real estate lease obligations. The reserve associated with lease obligations could be materially affected by factors such as the ability to obtain subleases, the creditworthiness of sub-lessees, market value of properties, and the ability to negotiate early termination agreements with lessors. While we believe that our current estimates regarding lease obligations are adequate, future events could necessitate significant adjustments to these estimates.

Accounting for Litigation, Commitments and Contingencies – We are currently involved in certain legal proceedings, which, if unfavorably determined, could have a material adverse effect on our operating results and financial condition. In connection with our assessment of these legal proceedings, we must determine if an unfavorable outcome is probable and evaluate the costs for resolution of these matters, if reasonably estimable. We have developed these determinations and related estimates in consultation with outside counsel handling our defense in these matters and are based upon an analysis of potential results, assuming a combination of litigation and defense strategies. See Item 1 “Legal Proceedings” and Note 11 to our unaudited condensed consolidated financial statements included in this quarterly report on Form 10-Q.

The above listing is not intended to be a comprehensive list of all of our accounting policies. In many cases, the accounting treatment of a particular transaction is specifically dictated by generally accepted accounting principles, with no need for management’s judgment in their application. There are also areas in which management’s judgment in selecting any available alternative would not produce a materially different result. See our audited consolidated financial statements and notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2002 which contain accounting policies and other disclosures required by generally accepted accounting principles.

RESULTS OF OPERATIONS

THREE MONTHS ENDED MARCH 31, 2003 COMPARED TO THREE MONTHS

ENDED MARCH 31, 2002

Revenues

The Company’s total revenues increased to $121.1 million during the three months ended March 31, 2003 from $107.9 million for the same period in 2002, an increase of $13.2 million or 12.2%. Revenues from systems sales increased to $32.5 million during the three months ended March 31, 2003 (26.9% of total revenues) from $27.2 million for the same period in 2002 (25.2% of total revenues), an increase of $5.3 million or 19.6%. Software license revenue increased $2.5 million and hardware and third party software revenue increased $2.8 million as compared to the prior year.

Revenues from maintenance and service fees increased to $88.5 million during the three months ended March 31, 2003 (73.1% of total revenues) from $80.7 million for the same period in 2002 (74.8% of total revenues), an increase of $7.9 million or 9.8%. The increase was due to a $2.7 million increase in IDX’s core business maintenance revenue primarily resulting from annual maintenance price increases combined with an increase in installed base, a $3.5 million increase in installation, consulting and other services provided by IDX’s core business and a $1.7 million increase in EDiX’s medical transcription service fee revenue.

Cost of Sales

The cost of system sales increased to $11.8 million during the three months ended March 31, 2003 from $9.2 million for the same period in 2002, an increase of $2.6 million or 27.8%. The increase in cost of system sales is primarily a result of an increase in hardware included as a component of sales of the Company’s systems sales. The gross margin on systems sales decreased to 63.8% during the three months ended March 31, 2003 from 66.1% for the same period in 2002. Fluctuations in the gross profit margin as a percentage of system sales

Page 19 of 38

Table of Contents

typically result from the revenue mix of software license revenue, which has a higher gross profit margin, and hardware and third party software sales, which have a lower gross profit margin. The decrease in the gross profit margin as a percentage of sales was primarily due to the increase in lower margin hardware and third party software sales as a component of system sales in first quarter 2003 as compared to first quarter 2002.

The cost of maintenance and services increased to $65.1 million during the three months ended March 31, 2003 from $62.9 million for the same period in 2002, an increase of $2.2 million or 3.5%. The increase in cost of maintenance and services resulted primarily from an increase in personnel costs related to medical transcription staff and an increase in depreciation and computer equipment maintenance fees. The gross profit margin on maintenance and service fees increased to 26.5% during the three months ended March 31, 2003 from 22.0% for the same period in 2002. The increase in margin was primarily due to increased maintenance revenue in IDX’s core business which was only partially offset by growth in service and maintenance expenses, offset by a decrease in EDiX’s gross profit margin due to higher labor and related costs as a percentage of total revenue.

The gross profit margin of maintenance and services of IDX’s core business, information systems and services, increased to 30.4% during the three months ended March 31, 2003 from 23.5% for the same period in 2002 primarily due to increased maintenance revenue which was only partially offset by growth in service and maintenance expenses. The gross profit margin for the Company’s medical dictation and transcription business segment (EDiX) decreased as a percentage of sales to 18.2% during the three months ended March 31, 2003 from 19.1% for the same period in 2002 due to higher labor and related costs as a percentage of total revenue.

Selling, General and Administrative Expenses

Total selling, general and administrative expenses increased to $24.6 million during the three months ended March 31, 2003 from $22.0 million for the same period in 2002, an increase of $2.6 million or 11.9%. As a percentage of total revenues, total selling, general and administrative expenses remained fairly flat at 20.3% for the three months ended March 31, 2003 as compared to 20.4% for the same period in 2002. Selling, general and administrative expenses for IDX’s core business increased to $20.1 million during the three months ended March 31, 2003 from $18.1 million for the same period in 2002, an increase of approximately $2.0 million or 10.7%. This increase is primarily due to personnel and increased rent expense. EDiX’s selling, general and administrative expenses increased to $4.5 million during the three months ended March 31, 2003 from $3.8 million for the same period in 2002, an increase of approximately $700,000 or 17.5%. This increase is due to a $260,000 increase in bad debt expense, additional insurance and professional expenses of $225,000 and increased personnel expenses of $225,000 in order to support increased revenue.

Software Development Costs

Total software development costs increased to $14.2 million during the three months ended March 31, 2003 from $12.1 million for the same period in 2002, an increase of $2.1 million or 17.4%. As a percentage of total revenues, total software development costs increased to 11.8% during the three months ended March 31, 2003 from 11.2% for the same period in 2002. As a percentage of total system sales, total software development costs decreased to 43.8% during the three months ended March 31, 2003 from 44.6% for the same period in 2002. The $2.1 million increase in total software development costs is primarily due to increased personnel costs of $1.2 million combined with a net increase in capitalized software development cost amortization, net of amounts capitalized, of approximately $900,000. Software development costs related to IDX’s core information systems and services business segment increased as compared to the prior year primarily due to increased salary costs of $1.0 million combined with a net increase in capitalized software development cost amortization, net of amounts capitalized of $900,000. Software development costs in the medical dictation and transcription business segment (EDiX) increased to $890,000 during the three months ended March 31, 2003 from $471,000 for the same period in 2002, an increase of $419,000. This increase is primarily due to increased personnel costs of approximately $250,000 and increased consulting costs of approximately $170,000.

As described in Note 1 of our audited consolidated financial statements and notes thereto contained in our Annual Report on Form 10K for the year ended December 31, 2002 which contain accounting policies and other

Page 20 of 38

Table of Contents

disclosures required by generally accepted accounting principles, software development costs incurred subsequent to the establishment of technological feasibility until general release of the related products are capitalized. Historically, costs incurred during beta site testing have not been material, however as the Company develops products that use more complex technologies as well as more comprehensive clinical systems, the time and effort required to complete beta site testing may be significantly more extensive. Consequently, capitalized software development costs may become more significant in future reporting periods. Approximately $114,000 and $870,000 of total software development costs were capitalized during the three months ended March 31, 2003 and 2002, respectively. Amortization of software development costs was approximately $580,000 and $432,000 during the three months ended March 31, 2003 and 2002, respectively.

Lease Abandonment Charge

In the three months ended December 31, 2002, the Company recorded a lease abandonment charge of $9.2 million in its core information systems and services business segment. The lease abandonment charge is related to asset impairment and rent obligations through 2005 under the lease agreement associated with the Company’s former Seattle office. In 2002, the Company determined it would consolidate its Seattle operations into the new office space and abandon the space subject to the former lease. The Company has been unable to secure a sub-tenant to assume its prior lease. The lease abandonment charge consisted of costs related to the net present value of future lease payments of approximately $7.9 million and non-cash write-offs of certain leasehold improvements of approximately $1.3 million. As of March 31, 2003, the Company had an accrual balance of $7.1 million primarily related to leased facilities, of which approximately $2.2 million will be paid during the remainder of 2003, and approximately $4.9 million thereafter. In the event that the Company is able to secure a sub-tenant to assume its prior lease in a future reporting period, the present value of the future sub-lease income would be recorded as a reduction in expenses under the lease abandonment caption in the financial statements in the period in which the sub-lease agreement is signed.

Interest Income (Expense)

Total interest income decreased to approximately $248,000 during the three months ended March 31, 2003 as compared to $329,000 for the same period in 2002. This decrease is primarily due to lower interest rates in the three months ended March 31, 2003 as compared to rates in the same period in 2002. Total interest expense increased to approximately $121,000 during the three months ended March 31, 2003 from $53,000 during the same period in 2002, primarily due to increased interest expense related to higher balances on short-term borrowings.

Gain on Sale of Investment in Subsidiary

On January 8, 2001, the Company sold certain of the net assets and operations of its majority owned subsidiary, ChannelHealth to Allscripts, a public company providing point-of-care electronic prescribing and productivity solutions for physicians. In addition to the sale, the Company entered into a ten-year strategic alliance agreement with Allscripts (the “Alliance Agreement”), whereby Allscripts is the exclusive provider of point-of-care clinical applications sold by the Company to physician practices.

Pursuant to the Alliance Agreement, the Company guaranteed that Allscripts gross revenues resulting from the alliance (less any commissions paid to the Company) would amount to at least $4.5 million for fiscal year 2001. Due to this contingency, IDX deferred $4.5 million of the gain as of the date of the transaction and recognized a gain of $35.5 million in 2001. An additional gain of $4.3 million was recognized in the first quarter of 2002 when the contingency was resolved. See Note 4 of the Notes to Condensed Consolidated Financial Statements.

Income Taxes

The Company recorded total income tax expense of approximately $1.6 million during the three months ended March 31, 2003, resulting in an effective tax rate of 30.0%. This is lower than the Company’s historical tax rate of 40.0% primarily due to the utilization of previously reserved net operating losses and research and experimentation credits to offset income taxes. The Company recorded income tax expense of approximately

Page 21 of 38

Table of Contents

$2.0 million during the three months ended March 31, 2002, an effective tax rate of 33.0%. This favorable rate is also primarily the result of research and experimentation credits. The Company anticipates a consolidated effective tax rate of approximately 30.0% for the year ending December 31, 2003. The net deferred tax assets as of March 31, 2003 of approximately $3.6 million are expected to be realized by generating future taxable income and are otherwise recoverable through available tax planning strategies.

LIQUIDITY AND CAPITAL RESOURCES

The Company principally has funded its operations, working capital needs and capital expenditures from operations and short-term borrowings under revolving secured bank lines of credit.

Net cash provided by or used in operations is principally comprised of net income or loss and is primarily affected by the net effect of the change in accounts receivable, accounts payable, accrued expenses and non-cash items relating to depreciation and amortization, deferred taxes, the sale of ChannelHealth, and certain components of lease abandonment and restructuring charges. Accounts receivable, deferred revenue and accounts payable fluctuate considerably due to the nature of the Company’s business, including, among other things, the length of installation efforts, which are dependent upon the size of the transaction, the changing business plans of the customer, the effectiveness of customers’ management and general economic conditions. During the three months ended March 31, 2003, accounts receivable from customers have been collected on average within 79 days, which represents a decrease of 8 days as compared to the year ended December 31, 2002 and a decrease of 7 days as compared to the three months ended March 31, 2002.

Cash flows related to investing activities have historically been related to the purchase of computer and office equipment, leasehold improvements and the purchase and sale of investment grade marketable securities. The Company invested approximately $6.5 million on the acquisition and implementation of an enterprise resource planning system during 2002 and plans to invest an additional amount of approximately $11.8 million during 2003 related to this system implementation.

In addition, investing activities may also include purchases of, interests in, loans to and acquisitions of businesses for access to complementary products and technologies. The Company expects to continue in these activities during 2003. In April 2002, the Company acquired a minority interest in Stentor, Inc., one of the Company’s strategic partners, by exercising a warrant to purchase 562,069 shares of preferred stock of Stentor, Inc. for $7.5 million. Each preferred share is convertible, at any time at the option of the holder, into one share of common stock of Stentor, Inc., subject to certain adjustments. In addition, the preferred shares are not entitled to dividends but are entitled to a liquidation preference equal to the amount paid by the Company to purchase such shares.

Cash flows from financing activities historically relate to the issuance of shares of the Company’s common stock through the exercise of employee stock options and in connection with the Company’s employee stock purchase plan and proceeds from the lines of credit.

Cash, cash equivalents and marketable securities at March 31, 2003 were $56.1 million, a decrease of $1.7 million from December 31, 2002. The Company entered into a new revolving line of credit agreement during the second quarter of 2002 allowing the Company to borrow up to $40.0 million, subject to certain restrictions. This line of credit is secured by deposit accounts, accounts receivable and other assets of the Company and certain of its subsidiaries and bears interest at the bank’s base rate plus .25%, which was approximately 5.0% as of March 31, 2003. This line of credit is subject to certain terms and conditions and will expire on June 27, 2005. At March 31, 2003, the Company had $23.7 million outstanding under this arrangement. As of March 31, 2003 the Company is in violation of a covenant pursuant to this line of credit related to cash flow. The Company has received a waiver from the lender. As of May 2, 2003, there was no outstanding balance on the revolving line of credit. At March 31, 2002, the Company had $18.7 million outstanding under a separate revolving demand line of credit with another bank allowing the Company to borrow up to approximately $19.0 million bearing interest at the bank’s base rate, approximately 4.0% in 2002. This line of credit was subject to certain terms and conditions including the requirement that the Company must maintain deposits with the bank that are in excess of the amounts borrowed.

Page 22 of 38

Table of Contents

In addition to existing financing arrangements, the Company owns, through a wholly owned subsidiary, approximately 7.5 million shares of common stock of Allscripts, a public company listed on the NASDAQ National Market under the symbol “MDRX”. This investment is accounted for under the equity method. The Company recorded an equity loss during 2001 of $17.6 million on a pre-tax basis that reduced the balance of the Company’s investment carrying balance in Allscripts to zero. The estimated market value of this investment is approximately $20.6 million as of March 31, 2003 based on the closing price per share of Allscripts common stock on March 31, 2003 on the NASDAQ National Market, and is subject to certain sale restrictions that may significantly impact the market value.

The cash sale of EDiX, as discussed in Note 13, is expected to have a positive effect on the liquidity of the Company. Sales proceeds, net of any income taxes or transaction expenses, will increase the cash and investment balances of IDX. The sale transaction is scheduled to close subject to customary closing conditions, including the expiration of the waiting period under the Hart-Scott-Rodino Act, on May 31, 2003.

In 2002, the Company entered into a $2.8 million stand-by letter of credit arrangement with a bank in compliance with a provision of an office space lease related to tenant improvements. The Company has no plans to default on the underlying payment obligation, and, therefore, has determined that the fair value of this contingent liability is zero. This stand-by letter of credit expires in June 2003.

The Company expects that its requirements for office facilities and other office equipment will grow as staffing requirements dictate. The Company’s operating lease commitments consist primarily of office leases for the Company’s operating facilities. The Company plans to increase its professional staff during 2003 as needed to meet anticipated sales volume and to support research and development efforts for certain products. To the extent necessary to support increases in staffing, the Company may obtain additional office space.

As of March 31, 2003, the Company has not entered into other material lease or purchase commitments not disclosed above or in the table below.

Operating leases

Of the $11.6 million due in 2003, $414,000 is due to 4901 LBJ Ltd. Partnership, a Vermont limited partnership (“LBJ”), a related party described below. All other amounts are due to unrelated third parties. Approximately $7.1 million of this obligation has been accrued in 2002 as a lease abandonment charge. See Note 5 of the Notes to Condensed Consolidated Financial Statements.

The Company believes that currently available funds will be sufficient to finance its operating requirements at least through the next twelve months. To date, inflation has not had a material impact on the Company’s revenues or income.

Page 23 of 38

Table of Contents

During the three months ended March 31, 2003, the Company did not engage in:

Richard E. Tarrant, Chairman of the Company’s Board of Director’s, is the President and a director of LBJ Real Estate Inc., a Vermont corporation (“LBJ Real Estate”). Certain executive officers of LBJ Real Estate are also directors or executive officers of the Company, including Robert H. Hoehl, a director of the Company, and John A. Kane, the Company’s Chief Financial Officer, who also serves as a director of LBJ Real Estate. The stockholders of LBJ Real Estate include Messrs. Tarrant and Hoehl and an independent individual. LBJ Real Estate holds a 1% general partnership interest in LBJ, and Messrs. Hoehl, Tarrant, and Kane and Mr. Robert F. Galin, the Company’s Senior Vice President of Sales, and two other employees of the Company hold 72.95% limited partnership interest.

The Company leases an office building from LBJ. Lease agreements are based on fair market value rents and are reviewed and approved by the Committee on Interested Director Transactions of the Board of Directors, which is comprised of independent directors. Total rent paid to LBJ was approximately $137,835 and $139,599 during the three months ended March 31, 2003 and 2002, respectively, related to this issue.

At the time of this filing, the stockholders of LBJ are considering the potential sale of this real estate to an unrelated third party. The potential sale of this real estate would have no impact on the Company’s financial condition or operations as the existing operating lease would transfer to the new owners. If a sale is not completed, the guidance in FIN 46 “Consolidations of Variable Interest Entities” may require consolidation effective in the third quarter of 2003. The impact of this consolidation on the Company’s results of operations and financial condition is not expected to be material.

NEW ACCOUNTING STANDARDS

In November 2002, the FASB issued FIN 45, “Guarantor’s Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others.” FIN 45 requires that upon issuance of a guarantee, the guarantor must recognize a liability for the fair value of the obligation it assumes under the guarantee. The disclosure provisions of FIN 45 are effective for financial statements of interim or annual periods ending after December 15, 2002. The provisions for initial recognition and measurement are effective on a prospective basis for guarantees that are issued or modified after December 31, 2002, irrespective of a guarantor’s fiscal year-end.

In January 2003, the FASB issued FIN 46, “Consolidation of Variable Interest Entities,” to expand upon and strengthen existing accounting guidance that addresses when a company should include in its financial statements the assets, liabilities and activities of another entity. Until now, a company generally has included another entity in its consolidated financial statements only if it controlled the entity through voting interests. FIN 46 changes that guidance by requiring a variable interest entity, as defined, to be consolidated by a company if that company is subject to a majority of the risk of loss from the variable interest entity’s activities or is entitled to receive a majority of the entity’s residual returns or both. FIN 46 also requires disclosure about variable interest entities that the company is not required to consolidate but in which it has a significant variable interest. The consolidation requirements of FIN 46 apply immediately to variable interest entities created after January 31, 2003 and to older entities in the first fiscal year or interim period beginning after June 15, 2003. Certain of the disclosure requirements apply in all financial statements issued after January 31, 2003, regardless of when

Page 24 of 38

Table of Contents

the variable interest entity was established. The Company is currently evaluating the requirements and impact, if any, of FIN 46 on its consolidated results of operations and financial position.

In June 2002, the FASB issued SFAS No. 146, “Costs Associated with Exit or Disposal Activities.” SFAS 146 supercedes EITF Issue No. 94-3, “Liability Recognition for Certain Employee Termination Benefits and Other Costs to Exit an Activity”. SFAS No. 146 requires that a liability for a cost associated with an exit or disposal activity be recognized and measured initially at fair value only when the liability is incurred. SFAS No. 146 is effective for exit or disposal activities that are initiated after December 31, 2002. The adoption of SFAS No. 146 did not have a material impact on the Company’s financial position or results of its operations.

In December 2002, the FASB issued SFAS No. 148, “Accounting for Stock-Based Compensation—Transition Disclosure, An Amendment of FASB Statement No. 123”. SFAS No. 148 provides alternative methods of transition for a voluntary change to the fair value based method of accounting for stock-based employee compensation. In addition, SFAS No. 148 amends the disclosure requirements of SFAS No. 123 to require more prominent and more frequent disclosure in financial statements regarding the effects of stock-based compensation. The provisions of SFAS No. 148 are effective for fiscal and interim periods ending after December 15, 2002. The Company will continue to apply APB No. 25 as the method used to account for stock-based employee compensation arrangements, where applicable, but has adopted the disclosure requirements of SFAS No. 148.

FORWARD-LOOKING INFORMATION AND FACTORS AFFECTING FUTURE PERFORMANCE

This Quarterly Report on Form 10-Q contains “forward-looking statements” as defined in Section 21E of the Securities Exchange Act of 1934. For this purpose, any statements contained in this Quarterly Report that are not statements of historical fact may be deemed to be forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “will” and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause results to differ materially from those indicated by these forward-looking statements, including among others, statements regarding the health care industry, statements regarding our products, product development and information technology, statements regarding future revenue or other financial trends, statements regarding future acquisitions, strategic alliances, or other agreements, and statements regarding our intellectual property. If any risk or uncertainty identified in the following factors actually occurs, our business, financial condition and operating results would likely suffer. In that event, the market price of IDX’s common stock could decline.

The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes in future operating results, financial condition or business over time.

Because of these and other factors, past financial performance should not be considered an indicator of future performance. Investors should not use historical trends to anticipate future results.

The following important factors affect the Company’s business and operations:

QUARTERLY OPERATING RESULTS MAY VARY. The Company’s quarterly operating results have varied in the past and may vary in the future. IDX expects its quarterly results of operations to continue to fluctuate. Because a significant percentage of IDX’s expenses are relatively fixed, the following factors could cause these fluctuations:

Page 25 of 38

Table of Contents

In light of the above, IDX believes that its results of operations for any particular quarter or fiscal year are not necessarily meaningful or reliable indicators of future performance.

IDX’S PROPOSED SALE OF EDIX CORPORATION MAY BE DELAYED OR MAY NOT HAPPEN. IDX has agreed to sell its subsidiary, EDiX Corporation, to Total eMed, Inc., a medical transcription company based in Franklin, Tennessee. The closing of this transaction is subject to customary conditions, including the expiration of the waiting period under the Hart-Scott-Rodino Act. There can be no assurance that all of the conditions to closing will be satisfied and that the proposed transaction with Total eMed, Inc. will occur. If the transaction is not completed or is substantially delayed, IDX could be subject to a number of risks that may have a material and adverse effect on its business and stock price, including:

FINANCIAL TRENDS. Although the Company’s results from operations have been fairly stable during 2002 and the first quarter of 2003, since 1999 the Company’s revenue and results from operations have been volatile. During 2000 and continuing 2001, certain of the Company’s customers delayed making purchasing decisions with respect to certain of the Company’s software systems resulting in longer sales cycles for such systems. Management believes such delays are due to a number of factors, including customer organization changes, government approvals, pressures to reduce expenses, product complexity, competition, and the September 11 national tragedy. While the Company believes these factors were temporary, they may continue to cause reductions or delays in spending for new systems and services in the future. If these delays reoccur, they may cause unanticipated revenue volatility, decreased revenue visibility and affect the future financial performance of the Company.

VOLATILITY OF STOCK PRICE. IDX has experienced, and expects to continue to experience, fluctuations in its stock price due to a variety of factors including:

Page 26 of 38

Table of Contents

These fluctuations have had a significant impact on the market price of our common stock, and may have a significant impact on the future market price of our common stock.

These fluctuations may affect operating results as follows:

NEW PRODUCT DEVELOPMENT AND RAPIDLY CHANGING TECHNOLOGY. To be successful, IDX must continuously enhance its existing products, respond effectively to technology changes, and help its customers adopt new technologies. In addition, IDX must introduce new products and technologies to meet the evolving needs of its customers in the healthcare information systems market. IDX may have difficulty in accomplishing this because of:

IDX is currently devoting significant resources toward the development of enhancements to its existing products, particularly in the area of Internet-based functionality and the migration of existing products to new hardware and software platforms, including relational database technology, object-oriented architecture and application service provider technology. However, IDX may not successfully complete these product developments or the adaptation in a timely fashion, and IDX’s current or future products may not satisfy the needs of the healthcare information systems market. Any of these developments may adversely affect IDX’s competitive position or render its products or technologies noncompetitive or obsolete.

CHANGES AND CONSOLIDATION IN THE HEALTHCARE INDUSTRY. IDX currently derives substantially all of its revenues from sales of financial, administrative and clinical healthcare information systems, medical transcription services and other related services within the healthcare industry. As a result, the success of IDX is dependent in part on political and economic conditions as they relate to the healthcare industry.

Virtually all of IDX’s customers and the other entities with which IDX has a business relationship operate in the healthcare industry and, as a result, are subject to governmental regulation, including Medicare and Medicaid regulation. Accordingly, IDX’s customers and the other entities with which IDX has a business relationship are affected by changes in such regulations and limitations in governmental spending for Medicare and Medicaid programs. Recent actions by Congress have limited governmental spending for the Medicare and Medicaid programs, limited payments to hospitals and other providers under such programs, and increased emphasis on competition and other programs that potentially could have an adverse effect on IDX’s customers and the other entities with which IDX has a business relationship. In addition, federal and state legislatures have considered proposals to reform the U.S. healthcare system at both the federal and state level. If enacted, these proposals could increase government involvement in healthcare, lower reimbursement rates and otherwise change the business environment of IDX’s customers and the other entities with which IDX has a business relationship. IDX’s customers and the other entities with which IDX has a business relationship could react to these proposals and the uncertainty surrounding these proposals by curtailing or deferring investments, including those for IDX’s products and services.

In addition, many healthcare providers are consolidating to create integrated healthcare delivery systems with greater market power. These providers may try to use their market power to negotiate price reductions for IDX’s products and services. If IDX is forced to reduce its prices, its operating margins would likely decrease. As the healthcare industry consolidates, competition for customers will become more intense and the importance of acquiring each customer will become greater.

Page 27 of 38

Table of Contents

COMPETITION FOR HEALTHCARE INFORMATION SYSTEMS. The market for healthcare information systems is intensely competitive, rapidly evolving and subject to rapid technological change. IDX believes that the principal competitive factors in this market include the breadth and quality of system and product offerings, the features and capabilities of the systems, the price of the system and product offerings, the ongoing support for the systems, the potential for enhancements and future compatible products.

Some of IDX’s competitors have greater financial, technical, product development, marketing and other resources than IDX, and some of its competitors offer products that we do not offer. The Company’s principal existing competitors include Eclipsys Corporation, McKesson Corporation, Medquist, Inc., Siemans AG, Epic Systems Corporation, GE Medical and Cerner Corporation. Each of these competitors offer a suite of products that compete with many of IDX’s products. There are other competitors that offer a more limited number of competing products. Many of IDX’s competitors have also announced or introduced Internet strategies that will compete with IDX’s Internet applications and services. IDX may be unable to compete successfully against these organizations. In addition, IDX expects that major software information systems companies, large information technology consulting service providers and system integrators, Internet-based start-up companies and others specializing in the healthcare industry may offer competitive products or services. In October 2001, Pfizer, IBM and Microsoft announced the creation of a joint venture known as Amicore to develop applications to automate the administrative, clinical and financial functions of a medical practice and connect the practice to groups, laboratories, pharmacies and other providers for physicians and physician groups.

PRODUCT LIABILITY CLAIMS. Any failure by IDX’s products that provide applications relating to patient medical histories, diagnostic procedures, and treatment plans could expose IDX to product liability claims for personal injury and wrongful death. These potential claims may exceed IDX’s current insurance coverage. Unsuccessful claims could be costly to defend and divert management time and resources. In addition, IDX cannot make assurances that it will continue to have appropriate insurance available to it in the future at commercially reasonable rates.

PRODUCT MALFUNCTION FINANCIAL CLAIMS. Any failure by IDX’s eCommerce electronic claims submission service, or by elements of IDX’s systems that provide elements of claims submitted by its clients could expose IDX to liability claims for incorrect billing and electronic claims. These potential claims may exceed IDX’s current insurance coverage. Unsuccessful claims could be costly to defend and divert management time and resources. In addition, IDX cannot make assurances that it will continue to have appropriate insurance available to it in the future at commercially reasonable rates.

KEY PERSONNEL. The success of IDX is dependent to a significant degree on its key management, sales, marketing, and technical personnel. To be successful IDX must attract, motivate, and retain highly skilled managerial, sales, marketing, consulting and technical personnel, including programmers, consultants and systems architects skilled in the technical environments in which IDX’s products operate. Competition for such personnel in the software and information services industries is intense. IDX does not maintain “key man” life insurance policies on any of its executives with the exception of Richard E. Tarrant. Not all of IDX personnel have executed noncompetition agreements. Such agreements, even if executed, are difficult and expensive to enforce, and enforcement efforts could result in substantial costs and diversion of management and technical resources.

GOVERNMENT REGULATION. Virtually all of IDX’s customers and the other entities with which IDX has a business relationship operate in the healthcare industry and, as a result, are subject to governmental regulation. Because IDX’s products and services are designed to function within the structure of the healthcare financing and reimbursement systems currently in place in the United States, and because IDX is pursuing a strategy of developing and marketing products and services that support its customers’ regulatory and compliance efforts, IDX may become subject to the reach of, and liability under, these regulations.

The federal Anti-Kickback Law, among other things, prohibits the direct or indirect payment or receipt of any remuneration for Medicare, Medicaid and certain other federal or state healthcare program patient referrals, or

Page 28 of 38

Table of Contents

arranging for or recommending referrals or other business paid for in whole or in part by the federal health care programs. Violations of the federal Anti-Kickback Law may result in civil and criminal sanction and liability, including the temporary or permanent exclusion of the violator from government health programs, treble damages and imprisonment for up to five years for each violation. If the activities of a customer of IDX or other entity with which IDX has a business relationship were found to constitute a violation of the federal Anti-Kickback Law and IDX, as a result of the provision of products or services to such customer or entity, was found to have knowingly participated in such activities, IDX could be subject to sanction or liability under such laws, including the exclusion of IDX from government health programs. As a result of exclusion from government health programs, IDX customers would not be permitted to make any payments to IDX.

The federal Civil False Claims Act and the Medicare/Medicaid Civil Money Penalties regulations prohibit, among other things, the filing of claims for services that were not provided as claimed, which were for services that were not medically necessary, or which were otherwise false or fraudulent. Violations of these laws may result in civil damages, including treble and civil penalties. In addition the Medicare/Medicaid and other federal statutes provide for criminal penalties for such false claims. If, as a result of the provision by IDX of products or services to its customers or other entities with which IDX has a business relationship, IDX provides assistance with the provision of inaccurate financial reports to the government under these regulations, or IDX is found to have knowingly recorded or reported data relating to inappropriate payments made to a healthcare provider, IDX could be subject to liability under these laws.

The Health Insurance Portability and Accountability Act of 1996 (HIPAA) contains provisions regarding standardization, privacy, security and administrative simplification in healthcare. As a result of regulations now proposed under HIPAA, IDX intends to make investments to support customer operations in areas, such as:

Although it is not possible to anticipate the final form of all regulations under HIPAA, IDX has made and expects to continue to make investments in product enhancements to support customer operations that are regulated by HIPAA. Responding to HIPAA’s impact may require IDX to make investments in new products or charge higher prices. It may be expensive to implement security or other measures designed to comply with any new legislation or regulation.

The United States Food and Drug Administration has promulgated a draft policy for the regulation of computer software products as medical devices under the 1976 Medical Device Amendments to the Federal Food, Drug and Cosmetic Act. To the extent that computer software is a medical device under the policy, IDX, as a manufacturer of such products, could be required, depending on the product, to:

Depending on the intended use of a device, the FDA could require IDX to obtain extensive data from clinical studies to demonstrate safety or effectiveness, or substantial equivalence. If the FDA requires this data, IDX would be required to obtain approval of an investigational device exemption before undertaking clinical trials. Clinical trials can take extended periods of time to complete. IDX cannot provide assurances that the FDA will approve or clear a device after the completion of such trials. In addition, these products would be subject to the Federal Food, Drug and Cosmetic Act’s general controls, including those relating to good manufacturing practices and adverse experience reporting. Although it is not possible to anticipate the final form of the FDA’s

Page 29 of 38

Table of Contents

policy with regard to computer software, IDX expects that the FDA is likely to become increasingly active in regulating computer software intended for use in healthcare settings regardless of whether the draft is finalized or changed. The FDA can impose extensive requirements governing pre- and post-market conditions like service investigation, approval, labeling and manufacturing. In addition, the FDA can impose extensive requirements governing development controls and quality assurance processes.

SYSTEM ERRORS AND WARRANTIES. IDX’s healthcare information systems are very complex. As with all complex information systems, IDX’s healthcare information systems may contain errors, especially when first introduced. IDX’s healthcare information systems are intended to provide information to healthcare providers for use in the diagnosis and treatment of patients. Therefore, users of IDX’s products may have a greater sensitivity to system errors than the market for software products generally. Failure of an IDX customer’s system to perform in accordance with its documentation could constitute a breach of warranty and require IDX to incur additional expenses in order to make the system comply with the documentation. If such failure is not timely remedied, it could constitute a material breach under a contract allowing the client to cancel the contract and subject IDX to liability.

POTENTIAL INFRINGEMENT OF PROPRIETARY RIGHTS OF OTHERS. If any of IDX’s products violate third party proprietary rights, IDX may be required to reengineer its products or seek to obtain licenses from third parties to continue offering its products without substantial reengineering. Any efforts to reengineer IDX’s products or obtain licenses from third parties may not be successful, in which case IDX may be forced to stop selling the infringing product or remove the infringing functionality or feature. IDX may also become subject to damage awards as a result of infringing the proprietary rights of others, which could cause IDX to incur additional losses and have an adverse impact on its financial position. IDX does not conduct comprehensive patent searches to determine whether the technologies used in its products infringe patents held by others. In addition, product development is inherently uncertain in a rapidly evolving technological environment in which there may be numerous patent applications pending; many of which are confidential when filed, with regard to similar technologies.

LIMITED PROTECTION OF PROPRIETARY TECHNOLOGY. IDX’s success and competitiveness are dependent to a significant degree on the protection of its proprietary technology. IDX relies primarily on a combination of copyrights, trade secret laws, patents, and restrictions on disclosure to protect its proprietary technology. Despite these precautions, others may be able to copy or reverse engineer aspects of IDX’s products, to obtain and use information that IDX regards as proprietary or to independently develop similar technology. Litigation may continue to be necessary to enforce or defend IDX’s proprietary technology or to determine the validity and scope of the proprietary rights of others. This litigation, whether successful or unsuccessful, could result in substantial costs and diversion of management and technical resources.

RISKS ASSOCIATED WITH ACQUISITION STRATEGY. IDX may grow in part through either acquisitions of complementary products, technologies and businesses or alliances with complementary businesses. IDX may not be successful in these acquisitions or alliances, or in integrating any such acquired or aligned products, technologies or businesses into its current business and operations. Factors which may affect IDX’s ability to expand successfully include:

Page 30 of 38

Table of Contents

STRATEGIC ALLIANCE WITH ALLSCRIPTS HEALTHCARE SOLUTIONS. In 2001, IDX entered into a ten-year strategic alliance with Allscripts to cooperatively develop, market and sell integrated clinical and practice management products.

During the term of the alliance, IDX is prohibited from cooperating with direct competitors of Allscripts to develop or provide any products similar to or in competition with Allscripts products in the practice management systems market. If the strategic alliance is not successful, or the restrictions placed on IDX during the term of the strategic alliance prohibit IDX from successfully marketing and selling certain products and services, IDX’s operating results may suffer. Additionally, if Allscripts or the Company breaches the strategic alliance, it may also leave the Company without critical clinical components for its information systems offerings in the physician group practice markets.

RESTRICTIONS ON LIQUIDATION OF INVESTMENT IN ALLSCRIPTS HEALTHCARE SOLUTIONS. In January 2001, IDX received approximately 7.5 million shares of common stock of Allscripts Healthcare Solutions in connection with the acquisition by Allscripts of IDX’s majority owned subsidiary, ChannelHealth Incorporated. IDX entered into a stock rights and restrictions agreement with Allscripts, pursuant to which, among other things, IDX agreed to restrictions on the sale of its shares of Allscripts common stock. Prior to January 2006, IDX is prohibited from selling more than 25% of its shares of Allscripts common stock in any one year, and 16.67% of such 25% in any one month. The restrictions on IDX’s ability to sell shares of Allscripts common stock may make it difficult for IDX to liquidate its investment in Allscripts and may adversely affect the value of such investment.

ANTI-TAKEOVER DEFENSES. IDX’s Second Amended and Restated Articles of Incorporation and Second Amended and Restated Bylaws contain certain anti-takeover provisions, which could deter an unsolicited offer to acquire IDX. For example, IDX’s board of directors is divided into three classes, only one of which will be elected at each annual meeting. These provisions may delay or prevent a change in control of IDX.

DISRUPTION IN THE ECONOMY. The terrorist events of September 11, 2001, as well as new terrorists threats, the war in Iraq and the possibility of war in other areas of the Middle East, have sensitized the Company and many other businesses to the potential disruption that such activities can have on the economy, the business cycle and, ultimately on the financial performance of these organizations. It is impossible to know whether such terrorist or military activities will continue, and whether, and to what extent, they may cause a disruption which may have a material adverse effect on the business and financial condition of the Company.

Item 3.    Quantitative and Qualitative Disclosures About Market Risk

IDX does not currently use derivative financial instruments. The Company generally places its securities available-for-sale investments in high credit quality instruments, primarily U.S. Government and Federal Agency obligations, tax-exempt municipal obligations and corporate obligations with contractual maturities of a year or less. We do not expect any material loss from our marketable security investments.

Internationally, IDX invoices customers in United States currency. The Company is exposed to minimal foreign exchange rate fluctuations and does not enter into foreign currency hedge transactions. Through March 31, 2003, foreign currency fluctuations have not had a material impact on our financial position or results of operations.

Investments in both fixed rate and floating rate interest earning instruments carry a degree of interest rate risk. Fixed rate securities may have their fair market value adversely impacted due to a rise in interest rates, while floating rate securities may produce less income than expected if interest rates fall. Due in part to these factors, our future investment income may fall short of expectations due to changes in interest rates or we may suffer losses in principal if forced to sell securities that may experience a decline in market value due to changes in interest rates. A hypothetical 10% increase or decrease in interest rates, however, would not have a material adverse effect on our financial condition.

Interest rates on short-term borrowings with floating rates carry a degree of interest rate risk. Our future interest expense may increase if interest rates fluctuate. Interest expense was immaterial in the first three months of 2003 and 2002.

Page 31 of 38

Table of Contents

Interest income on the Company’s investments is included in “Other Income”. The Company accounts for cash equivalents and securities available-for-sale in accordance with Statement of Financial Accounting Standards No. 115, “Accounting for Certain Investments in Debt and Equity Securities.” Cash equivalents are short-term highly liquid investments with original maturity dates of three months or less. Cash equivalents are carried at cost, which approximates fair market value. The Company’s investments are classified as securities available-for-sale and are recorded at fair value with any unrealized gain or loss recorded as an element of stockholders’ equity.

Item 4.    Controls and Procedures.

(a) Evaluation of disclosure controls and procedures. Based on their evaluation of the Company’s disclosure controls and procedures (as defined in Rules 13a-14(c) and 15d-14(c) under the Securities Exchange Act of 1934) as of a date within 90 days of the filing date of this Quarterly Report on Form 10-Q, the Company’s chief executive officer and chief financial officer have concluded that the Company’s disclosure controls and procedures are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and are operating in an effective manner.

(b) Changes in internal controls. There were no significant changes in the Company’s internal controls or in other factors that could significantly affect these controls subsequent to the date of their most recent evaluation.

PART II.    OTHER INFORMATION

Item 1.    Legal Proceedings

In late 2001, IDX finalized a “Cooperative Agreement” with a non-regulatory federal agency within the U.S. Commerce Department's Technology Administration, NIST, whereby the Company agreed to lead a $9.2 million, multi-year project awarded by NIST. The project entails research and development to be conducted by IDX and its partners in the grant. Subsequently, an employee of the Company made allegations that the Company had illegally submitted claims for labor expenses and license fees to NIST. The Company informed NIST of the employee’s allegations. The Company has conducted an investigation, and based on this investigation, the Company believes the employee’s allegations are without merit.

The Company believes the employee has likely filed an action under the Federal False Claims Act under seal in the Federal District Court for the Western District of Washington with respect to the alleged improper claims, sometimes referred to as a “Qui Tam” complaint. The Company has no information regarding the specific allegations in the Qui Tam complaint. Further, the Company has no information concerning the amount of money at issue in the Qui Tam complaint or in any action the employee may bring claiming damages for alleged retaliatory actions by the Company. The Company has not been informed if the U.S. Attorney’s office will pursue the claims. The Company has not yet been served with legal process detailing the allegations and no discovery has taken place. The Company believes that any allegations in the Qui Tam complaint are without merit, and the Company intends to vigorously defend against them.

In April 2003, the Company filed a complaint against the employee with the United States District Court for the Western District of Washington. The Company’s lawsuit asks the Court to grant a declaratory judgment stating that, should the Company terminate the employee’s employment, such action would not constitute retaliation for alleged whistle-blowing activities in violation of the Federal False Claims Act or the Sarbanes-Oxley Act and would not constitute a violation of the employee’s rights under other laws. The Company believes its lawsuit is meritorious and intends to vigorously pursue relief through prosecution of the lawsuit.

In May 2003, the employee filed a complaint against the Company with the U.S. Department of Labor, pursuant to Section 1514A of the Sarbanes-Oxley Act of 2002. The employee’s complaint asserts that, notwithstanding the employee’s allegations, Company management conspired to continue to defraud the government by allowing fraudulent activities to continue uncorrected and by concealing and avoiding its obligations to report any and all fraudulent activities to the proper authorities. In addition, the employee’s complaint alleges that the Company acted to retaliate, harass and intimidate the employee in contravention of the Sarbanes-Oxley Act’s whistleblower provisions. The employee’s complaint requests relief including, but not limited to, reinstatement, back-pay, with interest, and compensation for any damages sustained by the employee as a result of the alleged discrimination. The Company believes that all claims by the employee are without merit and will vigorously defend against them.

Page 32 of 38

Table of Contents

In April 2000, the Company commenced a lawsuit for damages caused by wrongful cancellation and material breach of contract by St. John Health System (SJHS), in the United States District Court for Eastern District of Michigan, entitled IDX Systems Corporation v. St. John Health System. Subsequently, SJHS commenced a lawsuit against the Company in the Circuit Court of Wayne County, Michigan, claiming unspecified damages against the Company for anticipatory repudiation, breach of contract, tort and fraud. On motion of the Company, SJHS’s lawsuit was removed to and consolidated in the federal court. In its answer to the Company’s lawsuit, SJHS asserted the same claims previously asserted in its state court action. In September 2001, SJHS specified damage claims of approximately $77.0 million in allegedly lost savings, and in January 2002 raised another theory of alleged unspecified damages for “cover.” On September 30, 2002, the United States District Court for the Eastern District of Michigan dismissed all of SJHS claims of fraud, tort and breach of contract, and alleged lost savings and consequential damages, leaving only its claim for anticipatory repudiation. On October 15, 2002, SJHS requested reconsideration of these rulings. On March 28, 2003, the Court denied SJHS’s request for reconsideration of its September ruling and also barred SJHS from introducing any evidence concerning, or making any arguments concerning, its claims for “cover” damages. The Company believes the claims of SJHS are without merit and continues to vigorously defend itself and prosecute its own claims for damages. The lawsuit is in the trial preparation stage and the parties are awaiting scheduling of the trial by the court.

From time to time, the Company is a party to or may be threatened with litigation in the ordinary course of its business. The Company regularly analyzes current information including, as applicable, the Company’s defenses and insurance coverage and, as necessary, provides accruals for probable and estimable liabilities for the eventual disposition of these matters.

Item 2.    Changes In Securities and Use of Proceeds

None.

Page 33 of 38

Table of Contents

Item 3.    Defaults Upon Senior Securities

Not applicable.

Item 4.    Submission of Matters to a Vote of Security Holders

None.

Item 5.    Other Information

Item 6.    Exhibits and Reports on Form 8-K

Page 34 of 38

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Page 35 of 38

Table of Contents

CERTIFICATIONS

I, James H. Crook, Jr., certify that:

Page 36 of 38

Table of Contents

CERTIFICATIONS

I, John A. Kane, certify that:

Page 37 of 38

Table of Contents

EXHIBIT INDEX

Page 38 of 38